Qilu Ruige CDK2/4/6 inhibitor RGT-419B was reported for the first time in China

On February 11, CDE's official website showed that Qilu Ruige's CDK2/4/6 inhibitor RGT-419B was declared for clinical use in China for the first time

RGT-419B is a next-generation CDK2/4/6 small molecule inhibitor with an optimized kinase activity profile

In cell model experiments, RGT-419B showed single-agent activity and greater inhibition of ER+ tumor cell growth than abemaciclib and palbociclib

As a single agent and in combination with other approved therapies, RGT-419B will initially be developed for the treatment of patients with HER2-, ER+ breast cancer who have primary or acquired resistance to currently approved CDK4/6 inhibitors

RGT-419B is the first of many innovative oncology drugs in development by Riage Pharma

HER2-/HR+ breast cancer is the most common type of breast cancer

Regor Therapeutics is a clinical-stage biopharmaceutical high-tech company

Ruige pharmaceutical official website pipeline

However, in early February, Pfizer sued the two founders of Rui Ge Medicine, accusing them of stealing the company's trade secrets while working at Pfizer, arguing that the drug launched by the defendant company was "strikingly similar" to Pfizer, and applied for a patent